Literature DB >> 18241284

Study of ABCB1 polymorphism (C3435T) in HIV-1-infected individuals from South India.

Siddharth Bakshi, Geetha Ramachandran, Karunaianandham Ramesh, Agibothu K Hemanthkumar, Suresh Anitha, Chandrasekaran Padmapriyadarsini, Gopalan Narendran, Pradeep A Menon, Sikhamani Rajasekaran, Soumya Swaminathan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18241284      PMCID： PMC2432492          DOI： 10.1111/j.1365-2125.2007.03093.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  10 in total

1.  The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells.

Authors:  M Hitzl; S Drescher; H van der Kuip; E Schäffeler; J Fischer; M Schwab; M Eichelbaum; M F Fromm
Journal:  Pharmacogenetics       Date:  2001-06

2.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Authors:  David W Haas; Heather J Ribaudo; Richard B Kim; Camlin Tierney; Grant R Wilkinson; Roy M Gulick; David B Clifford; Todd Hulgan; Catia Marzolini; Edward P Acosta
Journal:  AIDS       Date:  2004-12-03       Impact factor: 4.177

3.  A simple and rapid liquid chromatography method for simultaneous determination of zidovudine and nevirapine in plasma.

Authors:  Geetha Ramachandran; A K Hemanthkumar; V Kumaraswami; Soumya Swaminathan
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-07-03       Impact factor: 3.205

4.  Simple and rapid liquid chromatography method for determination of efavirenz in plasma.

Authors:  Geetha Ramachandran; A K Hemanth Kumar; Soumya Swaminathan; P Venkatesan; V Kumaraswami; David J Greenblatt
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-03-29       Impact factor: 3.205

5.  Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.

Authors:  Jacques Fellay; Catia Marzolini; Emma R Meaden; David J Back; Thierry Buclin; Jean Philippe Chave; Laurent A Decosterd; Hansjakob Furrer; Milos Opravil; Giuseppe Pantaleo; Dorota Retelska; Lidia Ruiz; Alfred H Schinkel; Pietro Vernazza; Chin B Eap; Amalio Telenti
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

6.  Frequency of C3435T polymorphism of MDR1 gene in African people.

Authors:  E Schaeffeler; M Eichelbaum; U Brinkmann; A Penger; S Asante-Poku; U M Zanger; M Schwab
Journal:  Lancet       Date:  2001-08-04       Impact factor: 79.321

7.  MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity.

Authors:  M M Ameyaw; F Regateiro; T Li; X Liu; M Tariq; A Mobarek; N Thornton; G O Folayan; J Githang'a; A Indalo; D Ofori-Adjei; D A Price-Evans; H L McLeod
Journal:  Pharmacogenetics       Date:  2001-04

8.  MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients.

Authors:  Thomas Illmer; Ulrich S Schuler; Christian Thiede; Ute I Schwarz; Richard B Kim; Sebastian Gotthard; Daniel Freund; Ulrike Schäkel; Gerhard Ehninger; Markus Schaich
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

9.  Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.

Authors:  Chantal Csajka; Catia Marzolini; Karin Fattinger; Laurent A Décosterd; Jacques Fellay; Amalio Telenti; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacol Ther       Date:  2003-01       Impact factor: 6.875

10.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

Authors:  S Hoffmeyer; O Burk; O von Richter; H P Arnold; J Brockmöller; A Johne; I Cascorbi; T Gerloff; I Roots; M Eichelbaum; U Brinkmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205
  10 in total
  1 in total

Review 1.  Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.

Authors:  Awewura Kwara; Geetha Ramachandran; Soumya Swaminathan
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.